Resumen
Background: Pathogenic germline mutations in several rare penetrant cancer predisposition genes are associated with an increased risk of aggressive prostate cancer (PC). Our objectives were to determine the prevalence of pathogenic germline mutations in men with low-risk PC on active surveillance, and assess whether pathogenic germline mutations associate with grade reclassification or adverse pathology, recurrence, or metastases, in men treated after initial surveillance. Methods: Men prospectively enrolled in the Canary Prostate Active Surveillance Study (PASS) were retrospectively sampled for the study. Germline DNA was sequenced utilizing a hereditary cancer gene panel. Mutations were classified according to the American College of Clinical Genetics and Genomics' guidelines. The association of pathogenic germline mutations with grade reclassification and adverse characteristics was evaluated by weighted Cox proportional hazards modeling and conditional logistic regression, respectively. Results: Overall, 29 of 437 (6.6%) study participants harbored a pathogenic germline mutation of which 19 occurred in a gene involved in DNA repair (4.3%). Eight participants (1.8%) had pathogenic germline mutations in three genes associated with aggressive PC: ATM, BRCA1, and BRCA2. The presence of pathogenic germline mutations in DNA repair genes did not associate with adverse characteristics (univariate analysis HR = 0.87, 95% CI: 0.36–2.06, p = 0.7). The carrier rates of pathogenic germline mutations in ATM, BRCA1, and BRCA2did not differ in men with or without grade reclassification (1.9% vs. 1.8%). Conclusion: The frequency of pathogenic germline mutations in penetrant cancer predisposition genes is extremely low in men with PC undergoing active surveillance and pathogenic germline mutations had no apparent association with grade reclassification or adverse characteristics.
| Idioma original | English |
|---|---|
| Páginas (desde-hasta) | 4332-4340 |
| Número de páginas | 9 |
| Publicación | Cancer Medicine |
| Volumen | 11 |
| N.º | 22 |
| DOI | |
| Estado | Published - nov 2022 |
Nota bibliográfica
Publisher Copyright:© 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Financiación
This study was supported by the Canary Foundation, NIH awards CA097186, U01 CA224255, and P30 CA015704, CDMPR awards, PC171001, PC170503, PC170510, PC170503P2, PC200262P1, the Prostate Cancer Foundation, and the Institute for Prostate Cancer Research. Funding information
| Financiadores | Número del financiador |
|---|---|
| Institute for Prostate Cancer Research | |
| National Institutes of Health (NIH) | PC171001, PC200262P1, PC170503P2, CA097186, PC170510, U01 CA224255 |
| National Childhood Cancer Registry – National Cancer Institute | P30CA015704 |
| Prostate Cancer Foundation | |
| Canary Foundation |
ODS de las Naciones Unidas
Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible
-
Good health and well being
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
- Oncology
- Cancer Research
Huella
Profundice en los temas de investigación de 'Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillance'. En conjunto forman una huella única.Citar esto
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver